Astellas furthers oncology ambitions with $765 million Medivation deal
This article was originally published in Scrip
Executive Summary
Astellas has acquired global rights to Medivation's investigational prostate cancer drug MDV3100, in an alliance worth up to $765 million in up-front and milestone payments to the US firm.
You may also be interested in...
Beyond The Pandemic, An Interview With Astellas’ Percival Barretto-Ko
Astellas Pharma US accounts for roughly one-third of the parent company’s annual revenues with a growing focus on immuno-oncology. The unit’s president discusses lessons from the pandemic, racial disparities in health care and business development.
Quick Listen: Scrip’s Five Must-Know Things
This time we touch on Pfizer’s R&D plans, real-world evidence for coronavirus vaccines, a new approval in lung cancer, challenges for Galapagos, and Takeda's pipeline story.
Daiichi's Novel EZH Candidate Progresses In New Consortium Trial
Japanese major links with new partners in European consortium to progress first-in-class molecule for multiple hematological malignancies.
Need a specific report? 1000+ reports available
Buy Reports